ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025
TEL AVIV, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including updated interim results from ENLIGHTED, the Company's ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade […]